Patents by Inventor Theodore Goodson, Jr.

Theodore Goodson, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Naphthyl acetamides as sPLA.sub.2 inhibitors
    Patent number: 6160175
    Abstract: A class of novel naphthyl acetamide compounds is disclosed together with the use of such compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: June 9, 1998
    Date of Patent: December 12, 2000
    Assignee: Eli Lilly and Company
    Inventors: Theodore Goodson, Jr., Richard W. Harper, David K. Herron
  • Naphthyl glyoxamides as SPLA.sub.2 inhibitors
    Patent number: 6090850
    Abstract: A class of novel naphthyl glyoxamide compounds of formula (I) is disclosed together with a process for making the novel naphthyl glyoxamide compounds and the use of such compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: June 9, 1998
    Date of Patent: July 18, 2000
    Assignee: Eli Lilly and Company
    Inventors: Theodore Goodson, Jr., David K. Herron
  • Phenyl glyoxamides as SPLA2 inhibitors
    Patent number: 5916922
    Abstract: A class of novel phenyl glyoxamides is disclosed together with the use of such compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: November 24, 1997
    Date of Patent: June 29, 1999
    Assignee: Eli Lilly and Company
    Inventors: Theodore Goodson, Jr., Richard Waltz Harper, David Kent Herron
  • Method of treating endotoxic shock in mammals
    Patent number: 5294613
    Abstract: This invention provides benzene derivatives, pharmaceutical formulations of those derivatives, and a method of using the derivatives for the treatment of inflammation in mammals.
    Type: Grant
    Filed: February 7, 1992
    Date of Patent: March 15, 1994
    Assignee: Eli Lilly and Company
    Inventors: Nancy G. Bollinger, Theodore Goodson, Jr., David K. Herron
  • Anti-inflammatory agents
    Patent number: 5098613
    Abstract: This invention provides benzene derivatives, pharmaceutical formulations of those derivatives, and a method of using the derivatives for the treatment of inflammation in mammals.
    Type: Grant
    Filed: July 11, 1990
    Date of Patent: March 24, 1992
    Assignee: Eli Lilly and Company
    Inventors: Nancy G. Bollinger, Theodore Goodson, Jr., David K. Herron
  • Anti-inflammatory agents
    Patent number: 4945099
    Abstract: This invention provides benzene derivatives, pharmaceutical formulations of those derivatives, and a method of using the derivatives for the treatment of inflammation in mammals.
    Type: Grant
    Filed: June 5, 1989
    Date of Patent: July 31, 1990
    Assignee: Eli Lilly and Company
    Inventors: Nancy G. Bollinger, Theodore Goodson, Jr., David K. Herron
  • Preparation of 4-fluoroazetidinones using FClO.sub.3
    Patent number: 4500456
    Abstract: 4-Fluoroazetidinone antibacterial agents are provided by a process comprising the reaction of an azetidinone-4-sulfinic acid, or a salt thereof, with perchloryl fluoride (FClO.sub.3) at -80.degree. C. to -25.degree. C., e.g., p-nitrobenzyl 3-methyl-2-(2-oxo-4-sulfino-3-phenoxyacetamido-1-azetidinyl-3-butenoate is reacted with FClO.sub.3 to provide corresponding 4-fluoroazetidinone. The latter is isomerized with a tertiary amine to corresponding 2-butenoate which a carboxy group deprotection provides an antibacterial compound.
    Type: Grant
    Filed: December 27, 1982
    Date of Patent: February 19, 1985
    Assignee: Eli Lilly and Company
    Inventors: Wayne A. Spitzer, Theodore Goodson, Jr.
  • Preparation of 4-haloazetidin-2-ones from 4-sulfinoazetidin-2-ones
    Patent number: 4368156
    Abstract: Process for 4-halo azetidinones of the formula ##STR1## wherein R.sub.1 is acylamino or diacylamino, X is chloro, bromo or iodo, and R is a carboxy-protecting group which comprises treating a 4-sulfinoazetidinone of the formula ##STR2## with positive halogen reagent, eg. N-chlorosuccinimide, N-bromosuccinimide, N-iodosuccinimide, hypohalite. The 4-haloazetidinones are useful intermediate for .beta.-lactam antibiotics.
    Type: Grant
    Filed: March 9, 1981
    Date of Patent: January 11, 1983
    Assignee: Eli Lilly and Company
    Inventors: Wayne A. Spitzer, Stjepan Kukolja, Theodore Goodson, Jr., Steven R. Lammert
  • Novel oxazolinoazetidinones and process therefor
    Patent number: 4357275
    Abstract: Novel oxazolinoazetidinone compounds are prepared by the reaction of chloroazetidinones with lead difluoride in dimethyl sulfoxide.
    Type: Grant
    Filed: September 18, 1980
    Date of Patent: November 2, 1982
    Assignee: Eli Lilly and Company
    Inventors: Wayne A. Spitzer, Theodore Goodson, Jr.
  • Process for novel oxazolinoazetidinones
    Patent number: 4243588
    Abstract: Novel oxazolinoazetidinone intermediates are prepared by cyclizing 2-chloroazetidinones with lead difluoride in dimethyl sulfoxide. The oxazolinoazetidinone products are useful as intermediates in the preparation of oxygen analogues of penicillins.
    Type: Grant
    Filed: June 19, 1979
    Date of Patent: January 6, 1981
    Assignee: Eli Lilly and Company
    Inventors: Wayne A. Spitzer, Theodore Goodson, Jr.
  • Process for preparing amino substituted .beta.-lactam antibiotics
    Patent number: 3962214
    Abstract: 6-Acylamino-6-alkylthiopenicillanic or 7-acylamino-7-alkylthiocephalosporanic acids or esters are reacted at a temperature between -80.degree. and -25.degree.C. with one equivalent of halogen to provide an intermediate halosulfonium halide which is reacted with a C.sub.1 -C.sub.4 alkyl amine, a C.sub.1 -C.sub.4 dialkylamine or ammonia in an appropriate solvent. The ester group is removed to provide the 6-aminopenicillanic or 7-aminocephalosporanic acid.
    Type: Grant
    Filed: July 11, 1974
    Date of Patent: June 8, 1976
    Assignee: Eli Lilly and Company
    Inventors: Theodore Goodson, Jr., Wayne A. Spitzer